Phase I/II dose-escalation trial of patupilone administered every 3 weeks (q 3 wk) in patients (pts) with relapsed/refractory ovarian, primary fallopian, or primary peritoneal cancer
ANNALS OF ONCOLOGY（2004）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要